Keros Therapeutics, Inc. - 8-K Filing

Keros Therapeutics approves $5 million share repurchase program following receipt of $20 million Takeda milestone payment. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $KROS

Read the full article at SEC EDGAR

More Regulatory news